Covid-19
[Press release – not published yet] Covid-19: Oxford vaccine offers less protection against South Africa variant
7 Feb, 2021 | 21:25h | UTCOxford Covid-19 vaccine trial results – University of the Witwatersrand
Commentaries: Covid: Oxford jab offers less S Africa variant protection – BBC AND Expert reaction to news reports that the Oxford/AZ vaccine gives limited protection against mild disease caused by the South African variant of SARS-CoV-2 – Science Media Centre AND Oxford/AstraZeneca COVID shot less effective against South African variant: study – Reuters
Commentary on Twitter (thread – click for more)
[Thread] 1. NEW Early data (not yet peer reviewed) shows the #AstraZeneca #CovidVaccine, that SA will start to administer this month, doesn't appear to offer protection against mild/moderate disease caused by the #501YV2 variant identified in the country. https://t.co/UWD0Xilner
— Mia Malan (@miamalan) February 7, 2021
Editorial: What went wrong in the global governance of covid-19?
7 Feb, 2021 | 21:27h | UTCWhat went wrong in the global governance of covid-19? – The BMJ
Related: The Five Things to Get Right Before the Next Pandemic – Bloomberg AND International collaboration and covid-19: what are we doing and where are we going? – The BMJ AND Why did the world’s pandemic warning system fail when COVID hit? – Nature AND One Year Later: COVID-19 Versus WHO And The World – Successes, Failures & Hopes – Health Policy Watch AND WHO’s Covid warnings were not heeded. Now the world has a new chance to beat the virus – The Guardian
The good and the (potentially) bad: What scientists know about variants and Covid-19 vaccines
7 Feb, 2021 | 21:23h | UTCThe good and the (potentially) bad: What scientists know about variants and Covid-19 vaccines – STAT
See also: What Will it Take to Make Covid-19 Vaccines Variant-Proof? – Wired AND What’s Going On With All These Coronavirus Variants? An Illustrated Guide – NPR AND Video: Coronavirus Variants – What They Mean – JAMA
SR/MA: ICU mortality from COVID-19 continued to fall in 2020, but improvement is slowing
7 Feb, 2021 | 21:18h | UTCNews release: ICU mortality from COVID-19 continued to fall in 2020, but improvement is slowing – University of Bristol
Original article: Mortality in patients admitted to intensive care with COVID‐19: an updated systematic review and meta‐analysis of observational studies – Anaesthesia
Commentary on Twitter
🔐Has mortality from COVID‐19 in patients admitted to the ICU changed again?@drrichstrong, @adk300, @emirakur and @doctimcook update their previous analysis and find that any fall in mortality rate between June and September appears to have plateaued.
🔗https://t.co/zp8ygzp78A pic.twitter.com/g21p3rcjY6
— 𝘈𝘯𝘢𝘦𝘴𝘵𝘩𝘦𝘴𝘪𝘢 (@Anaes_Journal) February 2, 2021
Cohort study: ECMO in patients with severe respiratory failure from COVID-19
7 Feb, 2021 | 21:16h | UTCRelated: ECMO for COVID-19 patients in Europe and Israel – Intensive Care Medicine
Commentaries on Twitter
#ECMO in #COVID19, multicenter US based study on 5122 critical adults
➡️#ECLS in 3.7%, 66.8% of whom survived to hospital discharge or 60 days
➡️considerably reduced mortality with early ECMO in severe hypoxemic respiratory failure vs conventional approachhttps://t.co/OgS7Q5tctS pic.twitter.com/PO5O8t3l8F— Intensive Care Medicine (@yourICM) February 4, 2021
Online today @yourICM, our important multicenter descriptive and trial emulation work around #ECMO and #COVID19 @BIDMCAnesthesia @DavidLeaf9 @SamanthaSkb273 @_MiguelHernan from the STOP-COVID Investigators https://t.co/DuhWufYqZ3 pic.twitter.com/nXPvKDYMYL
— Shaz Shaefi (@SShaefi) February 2, 2021
What’s the risk of dying from a fast-spreading COVID-19 variant?
7 Feb, 2021 | 21:21h | UTCWhat’s the risk of dying from a fast-spreading COVID-19 variant? – Nature
Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv
Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19
7 Feb, 2021 | 21:13h | UTC“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial